Professor Timo Minssen

Timo Minssen is Professor of Law at the University of Copenhagen (UCPH), and the Founding Director of UCPH's Center for Advanced Studies in Bioscience Innovation Law (CeBIL). He is also an LML Research Affiliate at the University of Cambridge (UK), and an Inter-CeBIL Research Affiliate, Petrie-Flom Centre for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School (US).

His research, supervision, teaching & part-time advisory practice concentrates on Intellectual Property-, Competition & Regulatory Law, as well as on the law & ethics of emerging health & life science technologies, such as genome editing, big data, artificial intelligence and quantum technology. This involves a plethora of legal issues emerging during the lifecycle of relevant products and processes - from the sustainable regulation of R&D and incentives for innovation to responsible technology transfer and commercialization.

Based on both his academic and practical experience from law firms, courts & life science start-ups, Timo serves as a member of several international committees and as an advisor to the WHO, WIPO, EU Commission, various organizations, companies, national governments and law firms. He presents his research at international symposia, major law firms, the Universities of Oxford, Cambridge, Hong Kong & Tokyo, Harvard Law School, Harvard Business School, Stanford Law School, Yale, MIT, the Broad institute, as well as at the  WHO, WIPO, European Medicines Agency and National Ehics Councils etc. His publications comprise 7 books, as well as 200+ articles and book chapters. Timo's research has been featured in i.a. The Economist, The Financial Times, El Mundo, Politico, WHO Bulletin, Times of India & Times Higher Education, and published in leading journals, such as Science, JAMA, NEJM Catalyst, Harvard Business Review, Harvard Business Manager, Nature Biotechnology, Nature Genetics, Nature Electronics, Nature PJ Digital Medicine, The Lancet Digital Health, PLoS-Computational Biology, Biotech. J., Drug Discovery, JLB, BLR, Person.Med., IIC, EIPR, ECLR, JIPLP, GRUR Int., Chi.-Kent J. Intell. Prop., IPQ, QMJIP, NIR & EUConst.LR. He is also a regular contributor on Harvard Law School's "Bill of Health" blog.